NanoLogix CEO expects FDA to clear diagnostic tests for bacteria

06/12/2011 | MedCityNews.com

NanoLogix CEO Bret Barnhizer said the Ohio-based company expects to secure in the next few months FDA clearances for several diagnostic tests, which can rapidly detect a wide range of bacteria. One of the company's products is BioNanoPore technology, which is being tested in two clinical trials to determine its ability to spot Group B Streptococcus.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD